The LDN Side Effect Survey Results from 2020 - Jill Brook, MA (2021 Conference) (LDN, low dose naltrexone)

Jill Brook, MA is a Research Advisor to the LDN Research Trust. In this presentation she shares the results of the 2020 LDN Side Effect Survey.

Hypothyroidism - Dawn Ipsen, PharmD (2021 Conference) (LDN, low dose naltrexone)

Dr. Dawn Ipsen is a compounding pharmacist who presents on some roles low dose naltrexone (LDN) may have in helping patients with hypothyroidism. She discusses hypothyroidism, its prevalence, and treatment goals. 

Eosinophilic Esophagitis Is More Treatable Than You Think - Deanna Windham, DO (2021 Conference) (LDN, low dose naltrexone)

Addressing the inflammatory impact of psoriasis - Apple Bodemer, MD (2021 Conference) (LDN, low dose naltrexone)

Atopic Dermatitis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

Atopic dermatitis is a hereditary skin disorder, and the most common form of eczema. Dr. Smith reviews the pathophysiology and diagnostic criteria for atopic dermatitis, as well as some causes.

How to treat pathologic cell behaviors - Mark Cooper, PhD (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

Psoriasis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Sajad Zalzala, MD - What Patients Need to Know About Telemedicine (2019 Conference) (LDN, low dose naltrexone)

Sajad Zalzala, MD discusses what telemedicine is, its use and benefits, and about using LDN Direct telemedicine/LDN prescription business. Some telemedicine regulations are presented, as well as common conditions treated with LDN

Elissa Mullen, ND - Sleep - PTSD HPA Axis Dysregulation - LDN & The Gut Brain Barrier (2019 Conference) (LDN, low dose naltrexone)

She describes sleep dysregulation and presents patient cases and relevant research.